CANTON, Mass. ‐ March 15, 2018 – Organogenesis Inc., a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets, today announced its PuraPly® Antimicrobial (AM) wound management product is now available in a new, easy-to-use 1.6 cm disc size.
“A vast majority of wounds – including small ones – contain biofilm, which represents a serious challenge to wound healing,” said Gary S. Gillheeney, Sr., President and CEO of Organogenesis. “The new small size of PuraPly AM – which utilizes PHMB to manage bioburden while supporting healing – gives clinicians an exciting new option for treating a wide range of small wounds.”
PuraPly® and PuraPly AM are both FDA 510(k)-cleared Class II medical devices indicated for acute and chronic wound management across a wide variety of wound types, including partial- and full-thickness wounds, pressure ulcers, surgical wounds, trauma wounds, and venous and diabetic ulcers. Both products are available in a range of sizes to meet the needs of a variety of wound types.
PuraPly AM utilizes a novel technology—purified native collagen matrix embedded with polyhexamethylene biguanide, or PHMB, a broad-spectrum antimicrobial. This unique combination of native collagen and PHMB helps manage the reformation of biofilm while supporting healing across a wide variety of wound types, regardless of severity or duration.
PuraPly AM has been named one of the “Top 10 Innovations in Podiatry” by Podiatry Today, an award-winning publication that covers the latest developments in podiatric medicine.